Relationship between PAI-1 gene 4G/5G polymorphism and clinical profile of IgA nephropathy.
- Author:
Rui DING
1
;
Xiang-mei CHEN
;
Shu-wen LIU
;
Yang LV
;
Jie WU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Child; Female; Gene Frequency; Genetic Predisposition to Disease; genetics; Genotype; Glomerulonephritis, IGA; genetics; pathology; Homozygote; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; genetics; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Young Adult
- From: Chinese Journal of Medical Genetics 2006;23(4):449-451
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEIt is clear that PAI-1 is a very important factor inhibiting extracellular matrix (ECM) degradation in the pathology process of IgA nephropathy (IgAN), so we design to investigate the relationship between PAI-1 promoter 4G/5G polymorphism and IgAN pathogenesis and progression.
METHODSClinical baseline data such as blood pressure, urinary protein excretion, serum profile, and extent of renal tissue damage at the time of renal biopsy were collected. The genotypes of PAI-1 were profiled by PCR-RFLP.
RESULTS(1) The distributions of genotype 4G 4G, 4G5G, 5G5G in PAI-1 gene promoter showed no significant difference between the IgAN group (0.33, 0.19, 0.48) and control group (0.3, 0.23, 0.47; chi-square =1.63, P>0.05); (2) There is an increasing frequency of 4G4G homozygote in the IgAN group who had severe pathology change proved by biopsy (0.39 vs 0.28; chi-square =7.86, P<0.05); in the patients group,the ones who carried 4G4G genotype got lower Ccr than 4G5G genotype cases did (P<0.05).
CONCLUSIONThe data here suggest that the 4G/5G polymorphism of PAI-1 is not a risk factor in IgAN etiology, but may facilitate the process of IgAN to end stage renal disease.
